Opana Generic Delay Deal Target of Another Class Action Lawsuit

Generic Line
Endo Pharmaceuticals and Impax Laboratories are facing a second proposed class action lawsuit over an alleged pay-to-delay deal that put off a generic launch of Endo’s pain medication Opana ER.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00